HTAs and rare diseases: How to assess their cost-effectiveness
Research output: Contribution to journal › Article › peer-review
Standard Standard
HTAs and rare diseases: How to assess their cost-effectiveness. / Hughes, D.; Phillips, C.J.; Hughes, D.A.
In: Pharmaceuticals Policy and Law, Vol. 13, No. 3-4, 01.11.2011, p. 161-165.
In: Pharmaceuticals Policy and Law, Vol. 13, No. 3-4, 01.11.2011, p. 161-165.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
Hughes, D, Phillips, CJ & Hughes, DA 2011, 'HTAs and rare diseases: How to assess their cost-effectiveness', Pharmaceuticals Policy and Law, vol. 13, no. 3-4, pp. 161-165. https://doi.org/10.3233/PPL-2011-0321
APA
Hughes, D., Phillips, C. J., & Hughes, D. A. (2011). HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law, 13(3-4), 161-165. https://doi.org/10.3233/PPL-2011-0321
CBE
Hughes D, Phillips CJ, Hughes DA. 2011. HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law. 13(3-4):161-165. https://doi.org/10.3233/PPL-2011-0321
MLA
Hughes, D., C.J. Phillips and D.A. Hughes. "HTAs and rare diseases: How to assess their cost-effectiveness". Pharmaceuticals Policy and Law. 2011, 13(3-4). 161-165. https://doi.org/10.3233/PPL-2011-0321
VancouverVancouver
Hughes D, Phillips CJ, Hughes DA. HTAs and rare diseases: How to assess their cost-effectiveness. Pharmaceuticals Policy and Law. 2011 Nov 1;13(3-4):161-165. doi: 10.3233/PPL-2011-0321
Author
RIS
TY - JOUR
T1 - HTAs and rare diseases: How to assess their cost-effectiveness
AU - Hughes, D.
AU - Phillips, C.J.
AU - Hughes, D.A.
PY - 2011/11/1
Y1 - 2011/11/1
U2 - 10.3233/PPL-2011-0321
DO - 10.3233/PPL-2011-0321
M3 - Article
VL - 13
SP - 161
EP - 165
JO - Pharmaceuticals Policy and Law
JF - Pharmaceuticals Policy and Law
SN - 1389-2827
IS - 3-4
ER -